A biotechnology company committed to developing novel therapies for autoimmune diseases, ImmuneWorks was founded in 2006 to develop safe and effective immune tolerance treatments for patients with serious autoimmune diseases of the lung. The scientific foundation of the company is ImmuneWorks' groundbreaking discovery that antigen-specific autoimmunity is responsible for the disease in over one-half of idiopathic pulmonary fibrosis (IPF) patients.

ImmuneWorks' initial focus is to develop and commercialize immune tolerance therapies and coupled diagnostic products to help people with IPF while building an immune tolerance platform in multiple autoimmune diseases.